Cooperative Agreement U01CA303465
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $695K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Seattle, WA 98109, USA
Similar Awards
- The National Cancer Institute awarded Fred Hutchinson Cancer Center $716,319 on June 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to optimize CD45-targeted astatine-211 radioimmunotherapy for malignant and non-malignant blood disorders. The funded work focuses on developing and refining astatine-211 (211AT) radioisotope-conjugated monoclonal antibodies targeting CD45, an antigen expressed on hematopoietic cells. The research builds on prior Phase 3 trial validation of...
- The National Cancer Institute awarded Fred Hutchinson Cancer Center $192,024 under the Cancer Research Manpower program (CFDA 93.398) on July 16, 2026, to support research on synthetic costimulation and signaling calibration for chimeric T cell receptors. The project, identified as K22CA303684, advances bispecific chimeric T cell receptor (BI-CHTCR) engineering to overcome limitations in current CAR T cell therapies for B cell malignancies. Existing CAR T cells frequently relapse due to...
- The National Institutes of Health National Cancer Institute awarded Fred Hutchinson Cancer Center $692,368 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate the MYC transcription factor network and its role in oncogenic and tumor-suppressive pathways. The research examines how dysregulation of MYC family transcription factors drives cancer initiation, progression, immune escape, and chemoresistance. The project uses genetically engineered...
- The National Cancer Institute awarded Fred Hutchinson Cancer Center $610,984 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to dissect Merkel cell polyomavirus (MCPYV) ALTO transcription and tumor suppression mechanisms in Merkel cell carcinoma (MCC). The project investigates how the ALTO tumor suppressor gene, which is silenced in MCC but downregulates MCPYV oncogenes and activates anti-viral immunity pathways when expressed, is regulated and exerts its...
- Federal Grant Award Summary Seattle Children's Research Institute received a $470,759 Project Grant from the National Cancer Institute (Cancer Treatment Research program, CFDA 93.395) effective September 1, 2025 through August 31, 2027. The award supports development of an innovative CAR-T (Chimeric Antigen Receptor T-cell) immunotherapy platform designed to overcome T-cell exhaustion in solid tumor treatment, specifically targeting hepatocellular carcinoma patients. The research deliverables...
- The National Cancer Institute awarded Fred Hutchinson Cancer Center $487,902 on July 10, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct genome-wide association studies interrogating cancer pleiotropy and shared genetic susceptibility mechanisms across multiple cancer types. The project leverages existing genomic data from large biobanks including the UK Biobank and All of Us to identify shared germline susceptibility regions underlying cancer risk. The...
- The National Cancer Institute awarded The Ohio State University $366,965 on August 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to identify viral and host variables that predict risk and therapeutic response in Epstein-Barr virus positive post-transplant lymphoproliferative disorder. PTLD represents the second most common and most deadly malignancy in solid organ transplant recipients, with aggressive subtypes carrying a median overall survival of approximately six months....
- The National Cancer Institute awarded Fred Hutchinson Cancer Center $752,751 on July 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to decipher tumor heterogeneity, metastatic spread, and treatment resistance in advanced bladder cancer through the Fred Hutch/UW Bladder Cancer Rapid Autopsy Program. The project builds on an existing resource established in 2015 that collects tumors and matched benign tissues from metastatic bladder cancer patients within hours of death, with...
- The National Institutes of Health National Cancer Institute awarded Fred Hutchinson Cancer Center $736,383 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate PTGES3 as a novel therapeutic target in advanced prostate cancer resistant to androgen receptor signaling inhibitors. The research addresses mechanisms by which prostate cancer escapes treatment with FDA-approved AR signaling inhibitors through AR reactivation. Fred Hutchinson will conduct...
- The U.S. Defense Health Agency awarded a $5,149,107 Project Grant to the Fred Hutchinson Cancer Center in Seattle, WA, under the Military Medical Research and Development program (CFDA 12.420). The grant supports research aimed at "Defining Human Correlates of Super-Evasive Disseminated Tumor Cells, Their Pathological Relevance and How to Eradicate Them" over the period of July 1, 2025 to June 30, 2029. The research will be conducted by the prominent non-profit medical research...